Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

May 7, 2026

Study Completion Date

May 7, 2026

Conditions
Pain
Interventions
DRUG

anakinra

intravenous injection of 100 milligrams anakinra

DRUG

Placebo

intravenous injection of 1 milliliter normal saline

OTHER

Nociceptive pain challenge

The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.

Trial Locations (1)

77030

RECRUITING

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Alan Prossin

OTHER

NCT05074485 - Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience | Biotech Hunter | Biotech Hunter